Top 10 Medical Startup Investors in Iceland in July 2025
A list of 10 angel investors and VC (Venture Capital) funds that invest in Medical startups based in Iceland. We rank investors based on the number of investments they made in Medical companies from Iceland. We update this investor list every month.Top 10 Medical Startup Investors in Iceland in July 2025
Investor | Medical Iceland investments |
---|---|
New Business Venture Fund | 8 |
Novator | 3 |
Frumtak Ventures | 2 |
Silicon Valley Bank | 2 |
Asabys Partners | 1 |
Brunnur Ventures | 1 |
Kvika Asset Management | 1 |
Flerie Invest | 1 |
Sigþór Sigmarsson | 1 |
Wellington Partners | 1 |
The New Business Venture Fund is an evergreen investment fund that actively contributes to the development and growth of the Icelandic economy by investing in promising innovation and start-up companies.The New Business Venture Fund invests at seed and early stage in promising growth companies with great business ideas and strong management anddevelopment teams.The New Business Venture Fund is a state owned investment fund intended to strengthen and develop the Icelandic venture capital market along with promoting startups and business in Iceland thus encouraging economic growth.
Show more
Investment focus
- Software, Health Care, Medical
- Seed, Funding Round, Series A
- Iceland, United States, China
Portfolio highlights
- HorseDay — HorseDay is a mobile application to track horse activities.
- Spectaflow — Spectaflow is a SaaS solution for accommodations businesses focused on improving housekeeping and maintenance workflows
- PayAnalytics — PayAnalytics, a leading pay equity and workforce analytics solution, aids companies in closing pay gaps and fostering workplace equity. Ensure compliance with pay transparency regulations, assess wage disparities, and analyze workforce demographics conveniently.
Novator is an alternative investment firm founded and led by the international investor and entrepreneur Thor Bjorgolfsson.Novator's investment portfolio is focused around following sectors: Telecommunications, Pharmaceuticals, IT and Renewable Energy. In addition, Novator operates a Private Equity Fund and a Credit Opportunities Fund.Novator focuses on developing strong management teams in each of its portfolio companies. While granting them the autonomy to create value, Novator maintains a supervisory role, principally through representation on the Boards of its investee companies. Novator differentiates itself from many other private equity companies in concentrating on complex situations, either by virtue of their structure or their cross-border nature. To create value, Novator undertakes the restructuring or "de-risking" of investment opportunities through re-financing, combining acquired assets with existing businesses, through sale to strategic or financial buyers, or through flotation. Novator's investment portfolio is focused around four main sectors:Telecommunications, Pharmaceuticals, IT and Renewable Energy.
Show more
Investment focus
- Software, E-Commerce, Online Games
- Funding Round, Series B, Series C
- United Kingdom, United States, Iceland
Portfolio highlights
- Nord Security — Nord Security is the leader in the field of online privacy and security. Our security tools have earned praise from respected experts and tech outlets.
- Better.com — Better Mortgage Corporation is a direct lender dedicated to providing a fast, transparent digital mortgage experience backed by superior customer support.
- Steel City Interactive — Steel City Interactive develops gaming.
At Frumtak Ventures, we champion founders who have demonstrated early traction and have potential to become global leaders in their space. We take a concentrated, high-conviction, and high-involvement approach to investing and dedicate ourselves to collaboratively work with our portfolio companies from the seed stage through IPO. Our initialticket size usually ranges from €1 million to €3 million.
Show more
Investment focus
- Software, Information Technology, Enterprise Software
- Seed, Funding Round, Series A
- Iceland, United States, United Kingdom
Portfolio highlights
- PLAIO — The only AI-assisted decision-making platform developed for pharmaceutical supply chain planning
- Moombix — Join us for the launch of our advanced learning platform for online music lessons
- Treble — We develop next generation sound simulation and spatial audio technology for digital twins and virtual worlds.
Silicon Valley Bank is the financial partner of the innovation economy; helping individuals and investors in the innovation ecosystem achieve extraordinary outcomes.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Debt Financing, Series B, Series A
- United States, United Kingdom, Canada
Portfolio highlights
- Chimerix — Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.
- Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
- TScan Therapeutics — Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien velit, aliquet eget commodo nec, auctor a sapien. Nam eu neque vulputate diam rhoncus faucibus. Curabitur quis varius libero.
Asabys Partners is a venture capital firm that invests across the board in human healthcare. The company is active in the health-tech and biopharma industries and aims to invest in Spain and abroad in innovative and transformative technologies. Asabys Partners are motivated by the idea of pushing the boundaries of science and medicine. This is donethrough the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry.
Show more
Investment focus
- Biotechnology, Medical Device, Health Care
- Series A, Seed, Series B
- Spain, France, Belgium
Portfolio highlights
- Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
- DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
- INBRAIN Neuroelectronics — We are scientists, doctors, techies and humanity lovers, with the mission of building neuroelectronic interfaces to cure brain disorders.
Brunnur Ventures is a top venture capital firm in Iceland for startups with high-growth potential.
Show more
Investment focus
- Software, SaaS, Gaming
- Seed, Series A, Funding Round
- Iceland, United States, Denmark
Portfolio highlights
- AviLabs — AviLabs specializes in software development in aviation.
- Laki Power — We supply power grid operators with advanced high-voltage line monitoring stations that enable them to optimise performance, safety and cost.
- Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.
Kvika Asset Management manages a broad range of funds including equity funds, bond funds and mixed funds.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Series A
- Iceland
Portfolio highlights
- PLAIO — The only AI-assisted decision-making platform developed for pharmaceutical supply chain planning
- EpiEndo Pharmaceuticals — Welcome to EpiEndo Pharma | Developing epithelial barrier enhancing drugs to treat chronic respiratory diseases
Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Funding Round, Series B
- Sweden, Israel, Iceland
Portfolio highlights
- Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
- Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
- Vitara Biomedical — Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.
Sigþór Sigmarsson is Finance director at Novato. He attended Háskóli Íslands.
Show more
Investment focus
- Software, Health Care, Banking
- Seed, Series D, Funding Round
- Iceland, United Kingdom
Portfolio highlights
- Genis — Genis is pioneering the development and application of therapeutic chitin derivatives.
- Treble — We develop next generation sound simulation and spatial audio technology for digital twins and virtual worlds.
- 3Z Pharmaceuticals — 3Z Pharmaceuticals provides research services intended to provide drug development services. It offers drug screening on sleep and epilepsy assays that helps in the development of drugs used to treat neurological disorders, enabling patients to get multiple drug efficacy and toxicity assays.Karl Karlsson and Haraldur Thorsteinsson founded 3ZPharmaceuticals in 2008. It based their company on their research on the sleeping patterns of the zebrafish at the Reykjavik University Neurolab in 2006.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Funding Round
- Germany, United States, United Kingdom
Portfolio highlights
- Hilo — Get stress-free readings round the clock with Hilo's clinically validated blood pressure monitor. Learn more
- HepaRegeniX — HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a keyregulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Investors by industry
Consumer
Proptech
Impact
Climate
Gaming
Biotech
FinTech
Marketplace
Community
Health Care
Hardware
Energy
Artificial intelligence
Google
EdTech
Sustainability
Venture Capital
Real Estate
Photography
Clean Energy
Education
B2B
Financial Services
Big Data
Payments
Finance
Organic Food
Food and Beverage
Web3
Infrastructure
Retail
Beauty
Publishing
Video Games
Music
Art
Wellness
Franchise
Mobile
Local
Digital Media
Legal
Android
eSports
Enterprise Software
Sports
Manufacturing
Email
Medical
Social Network
Social Media
Internet
Construction
Hospitality
Platforms
Biotechnology
Cannabis
Mobile Advertising
Travel
Fitness
Recruiting
Crowdfunding
Social
Medical Device
Automotive
Wine And Spirits
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Celebrity
Software
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
Canada
Germany
United Kingdom
Ireland
South Korea
India
Australia
New Zealand
United States
Middle East
Brazil
LATAM
Qatar
Indonesia
Asia
Europe
Spain
South Africa
Singapore
Armenia
Saudi Arabia
Sri Lanka
China
Africa
Oceania
Japan
Vietnam
Belarus
Chile
Belgium
Hong Kong
Finland
Ghana
Georgia
Ethiopia
Gibraltar
Faroe Islands
Denmark
Egypt
Estonia
Costa Rica
Hungary
Greece
Barbados
Croatia
Belize
Bahrain
Czech Republic
Algeria
Ecuador
Bulgaria
Bermuda
France
Kuwait
Malta
Morocco
Nicaragua
Mali
Lithuania
Peru
Lebanon
Jersey
Norway
Myanmar
Mauritius
Liberia
Mexico
Malaysia
Liechtenstein
Philippines
Italy
Israel
Panama
Poland
Senegal
Sierra Leone
Tunisia
Togo
Serbia
Turkey
San Marino
Thailand
Uzbekistan
Taiwan
Sweden
Tanzania
Slovenia
El Salvador
Portugal
Tajikistan
Ukraine
Puerto Rico
Uganda
Venezuela
Uruguay
Zambia
Zimbabwe
Rwanda
Russian Federation
Dominican Republic
Nigeria
Iraq
Azerbaijan
Bahamas
Iceland
Namibia
United Arab Emirates
Jamaica
Honduras
Bolivia
Isle of Man
Luxembourg
Albania
Pakistan
Grenada
Jordan
Bangladesh
Argentina
Romania
Kenya
Kazakhstan
Cayman Islands
Cambodia
Latvia
Cyprus
Oman
Colombia
Cameroon
Austria
Switzerland
Seychelles
Guatemala
Marshall Islands
Investors in Iceland by industry
Art
Manufacturing
Financial Services
Marketplace
Climate
Education
Payments
Food and Beverage
Medical
Medical Device
Internet
Android
Music
Mobile
Software
Sports
Enterprise Software
FinTech
Platforms
Enterprise
Health Care
Biotech
EdTech
SaaS
Community
Gaming
Social
Video Games
Sustainability
Hardware
Big Data
Artificial intelligence
Impact
Travel
Biotechnology
Energy
Media (entertainment)
Transportation